全國服務(wù)咨詢熱線：
18438616290
<b id="grzca"><menuitem id="grzca"></menuitem></b>
18438616290
簡要描述：Cerdulatinib 1198300-79-6Cerdulatinib(PRT-062070; PRT2070) is an novel oral dual Syk/JAK inhibitor.
產(chǎn)品型號：abs47028059廠商性質(zhì)：生產(chǎn)廠家更新時間：2026-01-15訪 問 量：614產(chǎn)品分類
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 1198300-79-6 |
|---|---|---|---|
| 分子式 | C20H27N7O3S | 純度 | 98% |
| 分子量 | 445.54 | 貨號 | abs47028059 |
| 規(guī)格 | 10mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | is an novel oral dual Syk/JAK inhibitor. | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Cerdulatinib 1198300-79-6
| 產(chǎn)品描述 | |
| 描述 | Cerdulatinib(PRT-062070; PRT2070) is an novel oral dual Syk/JAK inhibitor. |
| 純度 | 98% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 賽度替尼; PRT062070；PRT2070 |
| 外觀 | white powder |
| 可溶性/溶解性 | DMSO : ≥ 30 mg/mL (67.33 mM) |
| 生物活性 | |
| 靶點(diǎn) | JAK |
| In vivo(體內(nèi)研究) | PRT062070 (0.5 mg/kg) results in a nonstatistically significant trend toward reduced ankle inflammation, whereas significant reductions in inflammation are achieved with the 1.5, 3, and 5 mg/kg doses. PRT062070 also affects anticollagen antibody formation. PRT062070 (15 mg/kg) suppresses upregulation of splenic B-cell surface CD80/86 and CD69, and inhibits BCR signaling and activation in the spleen after oral dosing in mice. |
| 參考文獻(xiàn) | |
| 參考文獻(xiàn) |
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | Cell CycleKinases/PhosphatasesCdks EpigeneticsCell cycleKinases/PhosphatasesCdks ImmunologyImmune System DiseasesAntiviral SignalingHIV-related MicrobiologyProteinHuman ProteinDefensin Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
地址：上海市浦東新區(qū)新浩路58號申江科創(chuàng)園18棟
郵箱：
傳真：